Structured intelligence coverage

Structured records are temporarily unavailable. The published profile and its source ledger remain accessible.

Identity checks do not refresh the age of governance evidence. Open a record for its source date and review state.

Overview

Business, legal identity, ownership structure and classifications.

What the company does

About

Ironwood Pharmaceuticals, Inc. operates as a healthcare enterprise primarily dedicated to discovering, developing, and commercializing therapeutic solutions for gastrointestinal (GI) conditions. Its flagship commercial product is linaclotide, a guanylate cyclase type-C (GC-C) agonist.

Sector and industry values retain their source labels. A classification provider, taxonomy version and assignment date are not established unless the cited record states them.

Stable business record

Identity and status

Ownership and listing state

Public listing published

Ownership not asserted

The canonical public record includes at least one active security listing.

Inspect status source
Legal name
IRONWOOD PHARMACEUTICALS INC
Inspect source
Country
US
Inspect source
Sector
Healthcare
Inspect source
Industry
Drug Manufacturers - Specialty & Generic
Inspect source

Source-backed public-market identity

Index memberships

Current memberships are attached to a specific security and listing. Announcements, effective dates, and removals remain distinct states; Alpha does not infer membership from company size, exchange, or reputation.

No current membership is published in Alpha's tracked index universe.

This is not evidence that the company is absent from every market index.

As of Sep 27, 2026. Rights-filtered public evidence only; no redistribution or model training is granted.

Only source-backed memberships with an explicit public redistribution basis are returned.

Relationships and related records

Connections

Explore the roles, education and affiliations published in this record.

Alexander Denner

Open Alexander Denner profile →
Alexander DennerAlexander DennerAlexander Denner, …Alexander Denner, Ph.D.Catherine MoukheibirCatherine MoukheibirGregory MartinezGregory MartinezGregory MartiniGregory MartiniJay ShepardJay ShepardJohn MinardoJohn MinardoJon DuaneJon DuaneJulie McHughJulie McHughMark Currie, Ph.D.Mark Currie, Ph.D.Marla KesslerMarla KesslerMichael Shetzline,…Michael Shetzline, M.D., Ph.D.IRONWOOD PHARMACEU…

Dashed lines mark past roles. Select a connection to see its dates and sources.

Published record

Featured coverage

Selected publications and public sources used to establish this profile. Inclusion records provenance; it is not an endorsement.

Source 1 · canonical_identityAlpha canonical company public projectionSupports Company identity, Published leadership, Entity status boundary. Reviewed Sep 27, 2026.Open source

Board & Leadership

Board leadership, management, committees and their disclosed responsibilities.

Committee appointments · Temporarily unavailable

Structured records for this section are unavailable. This does not establish that no records exist. Published profile sources remain in Evidence & History.

Canonical AEGIS identity graph

Executive leadership

Current, confirmed roles are shown only when both the person Profile and supporting source record satisfy the public projection boundary. A missing role is not evidence that it does not exist.

Executive team

5 public records

Governance leadership

Boards & Committees

Board and committee assignments appear only when the canonical public projection retains a current role and supporting source. Unpublished records are not interpreted as absence.

Record as of Sep 27, 2026. Chair, executive office, Lead Independent Director and committee appointments retain their separate source roles. A complete board composition denominator and committee charters are not established by a partial roster.

Board roles

13 public records

Disclosure boundary

Governance and independence

Only current, confirmed leadership roles with public evidence are included in the canonical projection.

RecordStatusAuthorityEffective

Absence of a leadership role, committee, or disclosure is not evidence that it does not exist.

Financials & Filings

Reported statements, original filings and proxy disclosures with their reporting periods.

Financial statements · Temporarily unavailable

Structured records for this section are unavailable. This does not establish that no records exist. Published profile sources remain in Evidence & History.

Filing library · Temporarily unavailable

Structured records for this section are unavailable. This does not establish that no records exist. Published profile sources remain in Evidence & History.

Proxy & Voting · Temporarily unavailable

Structured records for this section are unavailable. This does not establish that no records exist. Published profile sources remain in Evidence & History.

Ownership & Markets

Ownership, funding and dated financial information.

Ownership, control and market context · Temporarily unavailable

Structured records for this section are unavailable. This does not establish that no records exist. Published profile sources remain in Evidence & History.

Ownership disclosures retain their reporting dates and source types. Economic ownership, investment discretion and voting authority are distinct. Activism and settlement-dated short interest are not established by holdings or short-sale volume.

Risk & Assurance

Disclosed coverage, ratings and assurance scope.

Disclosures and oversight · Temporarily unavailable

Structured records for this section are unavailable. This does not establish that no records exist. Published profile sources remain in Evidence & History.

Credit-rating evidence, where published, appears in the Governance and Basis sections with its source and reporting date. Insurance coverage, cyber ratings and assurance reports require their own issuer, scope, date and usage rights. Indemnification does not establish insurance coverage.

Evidence & History

Identifiers, sources and record limitations.

Identifiers

Alpha ID
alpha:company:46862e3a-c1fa-4f6c-b6e7-1531dd603a31
Record version
public-1

Sources

Sources and published information

Published evidence records

3 evidence records, matching Agent View. Records may refer to different locations or observations in the same document. This count is not a count of independent corroborating sources.

  1. Alpha canonical company public projection

    canonical identity · Source published: Date unavailable · Retrieved: Sep 27, 2026

    Supports 5 claims
    • Legal Name: IRONWOOD PHARMACEUTICALS INC · Claim reviewed: Sep 27, 2026
    • Entity Status: Public listing published · Claim reviewed: Sep 27, 2026
    • Published Fact: US · Claim reviewed: Sep 27, 2026
    • Published Fact: Healthcare · Claim reviewed: Sep 27, 2026
    • Published Fact: Drug Manufacturers - Specialty & Generic · Claim reviewed: Sep 27, 2026

  2. SEC DEF 14A 0001104659-26-050325

    sec def 14a · Source published: Apr 28, 2026 · Retrieved: Sep 6, 2026

    Supports 11 claims
    • Leadership Role: Julie McHugh: Chair of the Board · Claim reviewed: Sep 27, 2026
    • Leadership Role: Alexander Denner, Ph.D.: Director · Claim reviewed: Sep 27, 2026
    • Leadership Role: Jay Shepard: Director · Claim reviewed: Sep 27, 2026
    • Leadership Role: Mark Currie, Ph.D.: Director · Claim reviewed: Sep 27, 2026
    • Leadership Role: Marla Kessler: Director · Claim reviewed: Sep 27, 2026
    • Leadership Role: Thomas McCourt: Director, Chief Executive Officer · Claim reviewed: Sep 27, 2026
    • Leadership Role: Gregory Martinez: Senior Vice President, Chief Financial Officer · Claim reviewed: Sep 27, 2026
    • Leadership Role: John Minardo: Senior Vice President, Chief Legal Officer and Secretary · Claim reviewed: Sep 27, 2026
    • Leadership Role: Michael Shetzline, M.D., Ph.D.: Senior Vice President, Chief Medical Officer and Head of Research and Drug Development · Claim reviewed: Sep 27, 2026
    • Leadership Role: Tammy Gaskins: Senior Vice President, Chief Commercial Officer · Claim reviewed: Sep 27, 2026
    • Leadership Role: Thomas McCourt: Chief Executive Officer · Claim reviewed: Sep 27, 2026

  3. DEF 14A tm261380-1_def14a.htm

    sec proxy · Source published: Apr 28, 2026 · Retrieved: Sep 2, 2026

    Supports 7 claims
    • Leadership Role: Alexander Denner: Director · Claim reviewed: Sep 27, 2026
    • Leadership Role: Catherine Moukheibir: Director · Claim reviewed: Sep 27, 2026
    • Leadership Role: Gregory Martini: Director · Claim reviewed: Sep 27, 2026
    • Leadership Role: John Minardo: Director · Claim reviewed: Sep 27, 2026
    • Leadership Role: Jon Duane: Director · Claim reviewed: Sep 27, 2026
    • Leadership Role: Moukheibir Jay Shepard: Director · Claim reviewed: Sep 27, 2026
    • Leadership Role: Tammi Gaskins: Director · Claim reviewed: Sep 27, 2026